Biomarkers of sensitivity and resistance to the BTK inhibitor PCI-32765 in mantle cell lymphoma

被引：0
|
作者：
Balasubramanian, Sriram [1 ]
Chen, Jun [1 ]
Crowley, Richard [1 ]
Buggy, Joseph J. [1 ]
机构：
[1] Pharmacyclics Inc, Sunnyvale, CA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-856
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
856
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target
    Ponader, Sabine
    Balasubramanian, Sriram
    Pham, Lan V.
    Chen, Jun
    Tamayo, Archito T.
    Wang, Michael
    O'Brien, Susan
    Wierda, William G.
    Keating, Michael J.
    Ford, Richard J.
    Burger, Jan A.
    BLOOD, 2011, 118 (21) : 1576 - 1576
  • [2] Mast cell inhibition by the BTK inhibitor PCI-32765 as a potential therapy in pancreatic cancer
    Soucek, Laura
    Buggy, Joseph
    Kortlever, Roderik
    Swigart, Lamorna Brown
    Evan, Gerard I.
    CANCER RESEARCH, 2011, 71
  • [3] Targeting Btk in lymphoma:: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo
    Honigberg, Lee A.
    Smith, Ashley M.
    Chen, Jun
    Thiemann, Patti
    Vernet, Erik
    BLOOD, 2007, 110 (11) : 475A - 475A
  • [4] Biology of covalent BTK inhibitor PCI-32765 (Ibrutinib): From bench to bedside
    Chang, Betty Y.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [5] Identification of MicroRNA Markers of Sensitivity to the Novel Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Non-Hodgkin's Lymphoma
    Balasubramanian, Sriram
    Chen, Jun
    Honigberg, Lee
    Tee, Lillian
    Mamuszka, Hannah
    BLOOD, 2008, 112 (11) : 1155 - 1156
  • [6] First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma
    Furtado, M. V.
    Rule, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 47 - 48
  • [7] A clinical trial of the Bruton\#8217;s tyrosine kinase (Btk) inhibitor PCI-32765 in naturally occurring canine lymphoma
    Honigberg, Lee
    Smith, Ashley
    Loury, David
    Buggy, Joseph
    Thamm, Douglas
    CANCER RESEARCH, 2009, 69
  • [8] The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
    Dasmahapatra, Girija
    Patel, Hiral
    Dent, Paul
    Fisher, Richard I.
    Friedberg, Jonathan
    Grant, Steven
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 43 - 56
  • [9] Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
    Jennifer R. Brown
    Current Hematologic Malignancy Reports, 2013, 8 : 1 - 6
  • [10] Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
    Brown, Jennifer R.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 1 - 6
12345